Medications can help fight COVID-19 disease. COVID-19 medications, previously approved by the US Food and Drug Administration. USA (FDA), may promise to fight respiratory diseases caused by the SARS-CoV-2 coronavirus, according to a new modeling study by Northwestern Medical University of Texas. Center.
It can take months, even rapid approval, to develop new pharmaceutical agents that work against this virus, said Professor Hashem Sadek, lead author of the study. That is why we see drugs that are already FDA approved.
A strategy that has become increasingly popular in disease research. Most drugs exert their effects by binding to specific targets in the body or on disease-causing bacteria or viruses, connecting them to proteins, receptors, or channels to alter their function.
However, almost all drugs cause side effects due to off-target effects, which are associated with unexplained areas. Professor Sadek and his colleagues argued that some FDA-approved medications may inadvertently target vulnerable parts of SARS-CoV-2.
To test this idea, they conducted a computer-based study to extensively investigate what drugs might be useful against this coronavirus. They focused on the main protease (SARS-CoV-2 Mpro) of SARS-CoV-2, an enzyme used to bind long chains of viral proteins to host cells to self-replicate viruses. Direct and cut them into small pieces.
3D structure of the SARS-CoV-2 Mpro, in two different views. One protometer for the dimer is shown in light blue, the other in orange. Roman numerals are inscribed in the domain. The amino acid residues of the catalytic site are indicated as yellow and blue spheres for Cys145 and His41, respectively.
The asterisk marks a residue of protomer B (orange). The black regions indicate the position of Ala 285 of each of the two III domains. The terms in the chain are labeled N and C for molecule A (light blue) and N * and C * for molecule B (orange).
Scientists elsewhere have recently clarified the structure of this enzyme, including its binding pocket, said Professor Sadek. A drug that binds tightly to this binding pocket can block its function, making the virus unable to multiply and spread the infection.
To identify drug candidates, the researchers used a computer program to structurally unite all FDA drugs with binding pockets. They then manually examined which drugs, which are structurally adjusted, could ever form strong chemical bonds with pockets inside.
Two-dimensional presentation of the coupling poses for the 11 main drug candidates. The blue arrows are hydrogen trunk bonds and the green arrows are side chain hydrogen bonds. Unexpectedly, her main successes included several antiviral drugs.
Including darunavir, nalinavir, and saquinavir, which work by attacking proteases. However, scientists have identified several candidates that are far from the use of antivirals. These included the ACE inhibitor Moexipril.
The chemotherapeutic agents Daunorubicin and Mitoxantrone; Metamizole, a pain reliever; Bepotastine antihistamine and antimalarial atovaquone. One of the most promising candidates was rosuvastatin, a statin that is sold under the Crestor brand and is already being taken by millions of patients worldwide to lower cholesterol.
Although many candidates are unlikely to be able to deliver critically ill patients, such as chemotherapeutic agents, rosuvastatin already exhibits a strong safety profile, is inexpensive, and is readily available, said Professor Sadek.
Because this study was conducted entirely by computer, it is unknown if any of these candidates would be truly active against SARS-CoV-2, and additional validation studies are required before any clinical application.
But the study provides a starting point for other researchers to evaluate these drugs, both in the laboratory and in patients. Reassembling these FDA-approved drugs can be a quick method of treating patients who would otherwise have no choice.
The study is published on the prepress server ChemRxiv.org. Identification of FDA-approved drugs targeting the COVID-19 virus through structure-based drug repositioning. Researchers Will Examine Library of Antiviral Drugs to Counter COVID-19.
Scripps Research has announced that it will examine more than 14,000 compounds to see if there is any significant activity against COVID-19 for use in a therapy. Scripps Research, USA The US has announced that its teams are investigating possible antiviral medications that may be administered to patients already exposed to the COVID-19 coronavirus.
The institute’s goal is to quickly detect compounds in the clinic. According to the research institute, a priority is to test drugs already approved or with significant safety data available in humans for activity against the virus, since these drugs are available for the treatment of patients with coronavirus.
Scripps Research’s Division of Drug Development is using the Calibrate Collection, ReFRAME Drug Reurposing. The department has compiled ReFRAME. A collection of known drugs that contain more than 14,000 compounds that have been approved for other diseases by the United States Food and Drug Administration (FDA) or extensively tested for human safety.
Caliber has also developed an open source database containing preclinical and clinical data on these compounds. When the COVID-19 outbreak began, the department mobilized ReFRAME to begin the search for existing drugs and other compounds.
Previous studies have shown that some of these molecules appear effective against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Now, teams are testing all of the compounds against the new SARS-CoV-2 virus.
They are also investigating compounds that prevent the virus from initially infected cells. In a separate project, calibrate scientist Drs. Dennis is collaborating with Burton’s Scripps Research Laboratory to detect molecules that prevent SARS-CoV-2 from replicating after entering cells.
They hope that such a compound can serve as the basis for antiviral therapy. Another project being carried out by Calbride scientists is the detection of drugs that may increase the effectiveness of Gileadvir drug remedies that are currently being tested in five clinical trials of COVID-19.